Date Title Description PDF
27 Feb 2024 On P&L The Company releases the press release related to the full year 2023 financial results. Download
27 Feb 2024 On P&L The Company releases the full year 2023 financial results presentation. Download
27 Feb 2024 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
08 Nov 2023 On P&L The Company releases the press release related to the first nine months of 2023 financial results Download
08 Nov 2023 On P&L The Company releases the first nine months 2023 financial results presentation Download

Pages

Date Title Description PDF
28 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 20 December 2021 and 24 December 2021 Download
20 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 13 December 2021 and 17 December 2021 Download
17 Dec 2021 On business and financial situation ROVI reports that the CHMP has issued a positive opinion on Okedi® for the treatment for schizophrenia Download
13 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 6 December 2021 and 10 December 2021 Download
06 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 November 2021 and 3 December 2021 Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages